JP6882161B2 - 改善された幹細胞組成物 - Google Patents

改善された幹細胞組成物 Download PDF

Info

Publication number
JP6882161B2
JP6882161B2 JP2017504259A JP2017504259A JP6882161B2 JP 6882161 B2 JP6882161 B2 JP 6882161B2 JP 2017504259 A JP2017504259 A JP 2017504259A JP 2017504259 A JP2017504259 A JP 2017504259A JP 6882161 B2 JP6882161 B2 JP 6882161B2
Authority
JP
Japan
Prior art keywords
cells
ang1
culture medium
cell culture
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017504259A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512842A (ja
JP2017512842A5 (cg-RX-API-DMAC10.html
Inventor
シルヴィウ・イテスク
ポール・シモンズ
Original Assignee
メゾブラスト・インターナショナル・エスアーエールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014901247A external-priority patent/AU2014901247A0/en
Application filed by メゾブラスト・インターナショナル・エスアーエールエル filed Critical メゾブラスト・インターナショナル・エスアーエールエル
Publication of JP2017512842A publication Critical patent/JP2017512842A/ja
Publication of JP2017512842A5 publication Critical patent/JP2017512842A5/ja
Application granted granted Critical
Publication of JP6882161B2 publication Critical patent/JP6882161B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017504259A 2014-04-07 2015-04-07 改善された幹細胞組成物 Active JP6882161B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014901247A AU2014901247A0 (en) 2014-04-07 Improved stem cell composition
AU2014901247 2014-04-07
PCT/EP2015/057521 WO2015155187A1 (en) 2014-04-07 2015-04-07 Improved stem cell composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021024189A Division JP7196216B2 (ja) 2014-04-07 2021-02-18 改善された幹細胞組成物

Publications (3)

Publication Number Publication Date
JP2017512842A JP2017512842A (ja) 2017-05-25
JP2017512842A5 JP2017512842A5 (cg-RX-API-DMAC10.html) 2018-05-31
JP6882161B2 true JP6882161B2 (ja) 2021-06-02

Family

ID=53724311

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017504259A Active JP6882161B2 (ja) 2014-04-07 2015-04-07 改善された幹細胞組成物
JP2021024189A Active JP7196216B2 (ja) 2014-04-07 2021-02-18 改善された幹細胞組成物
JP2022198585A Active JP7571109B2 (ja) 2014-04-07 2022-12-13 改善された幹細胞組成物
JP2024176634A Pending JP2024177516A (ja) 2014-04-07 2024-10-08 改善された幹細胞組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021024189A Active JP7196216B2 (ja) 2014-04-07 2021-02-18 改善された幹細胞組成物
JP2022198585A Active JP7571109B2 (ja) 2014-04-07 2022-12-13 改善された幹細胞組成物
JP2024176634A Pending JP2024177516A (ja) 2014-04-07 2024-10-08 改善された幹細胞組成物

Country Status (9)

Country Link
US (4) US10400218B2 (cg-RX-API-DMAC10.html)
EP (2) EP3129468B1 (cg-RX-API-DMAC10.html)
JP (4) JP6882161B2 (cg-RX-API-DMAC10.html)
KR (2) KR102577698B1 (cg-RX-API-DMAC10.html)
CN (2) CN113337462A (cg-RX-API-DMAC10.html)
AU (4) AU2015243575B2 (cg-RX-API-DMAC10.html)
CA (1) CA2944262C (cg-RX-API-DMAC10.html)
SG (2) SG10202000644TA (cg-RX-API-DMAC10.html)
WO (1) WO2015155187A1 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048093A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
KR102577698B1 (ko) 2014-04-07 2023-09-12 메조블라스트 인터내셔널 에스에이알엘 개선된 줄기 세포 조성물
WO2015189063A1 (en) * 2014-06-10 2015-12-17 Mesoblast International Sàrl Treatment of immune disorders
JP6231709B1 (ja) * 2016-05-31 2017-11-15 シスメックス株式会社 蛍光画像分析装置および分析方法
EP3619294A1 (en) * 2017-05-04 2020-03-11 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
US12702683B2 (en) 2019-01-03 2026-08-11 Mesoblast International Sárl Method for improving visual acuity
CN113677790B (zh) * 2019-03-26 2024-05-24 普罗米瑟拉疗法公司 用于治疗慢加急性肝衰竭的成体肝祖细胞
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
WO2021176001A1 (en) 2020-03-05 2021-09-10 Mesoblast International Sàrl Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health, Inc. PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION
EP4229183A4 (en) 2020-10-14 2024-12-11 Ossium Health, Inc. Compositions and methods for extraction of mesenchymal stem cells
EP4228406A4 (en) 2020-10-14 2024-11-13 Ossium Health, Inc. SYSTEMS AND METHODS FOR BONE MARROW EXTRACTION AND CRYOPRESERVATION
EP4262831A4 (en) 2020-12-18 2025-01-01 Ossium Health, Inc. CELLULAR THERAPY PROCESSES
WO2022173737A1 (en) 2021-02-09 2022-08-18 Millennium Pharmaceuticals, Inc. Methods and compositions for freezing and thawing mammalian cells
JP2025538783A (ja) * 2022-12-09 2025-11-28 メゾブラスト・インターナショナル・エスアーエールエル 事前承認された組成物及び細胞培養方法
AU2023389700A1 (en) * 2022-12-09 2025-07-10 Mesoblast International Sarl Method of treating heart failure in subjects with persistent inflammation
WO2024121821A1 (en) * 2022-12-09 2024-06-13 Mesoblast International Sarl Conditioned media and use of the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
JP2001508302A (ja) 1997-01-10 2001-06-26 ライフ テクノロジーズ，インコーポレイテッド 胚性幹細胞血清置換
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AU2005209688A1 (en) * 1999-07-07 2005-10-06 Angioblast Systems, Inc. Mesenchymal precursor cell
JP2003052360A (ja) * 2001-08-20 2003-02-25 Japan Science & Technology Corp 基底膜細胞外基質を用いた間葉系幹細胞の培養方法
KR20050111593A (ko) * 2003-02-19 2005-11-25 가부시키가이샤 디나벡크 겐큐쇼 허혈질환의 치료방법
CN101103101B (zh) * 2004-09-24 2012-10-10 成血管细胞系统公司 增强间充质前体细胞（mpc）的增生和/或存活的方法
US8367405B2 (en) 2005-04-12 2013-02-05 Mesoblast, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
WO2007122233A1 (en) * 2006-04-25 2007-11-01 Vrije Universiteit Brussel Preparation of mesenchymal progenitor cells, particularly osteogenic progenitor cells
CN101407790B (zh) * 2008-10-30 2010-09-29 浙江大学 一种增强人骨髓间充质干细胞旁分泌能力的处理方法
EP2258413A1 (en) * 2009-06-04 2010-12-08 Université Catholique de Louvain Multi-dimensional biomaterial and method for producing the same.
JP5888670B2 (ja) * 2010-11-18 2016-03-22 国立大学法人東京工業大学 骨芽細胞分化誘導用培養基材、骨芽細胞分化誘導方法、及び骨芽細胞製造方法
CN102899293A (zh) * 2012-11-01 2013-01-30 上海市肺科医院 促血管生成素1基因修饰的间充质干细胞、及其构建方法与应用
KR102019540B1 (ko) * 2013-12-18 2019-09-06 아이디에이씨 홀딩스, 인크. 전이중 무선 시스템에서의 간섭 관리 방법, 장치 및 시스템
KR102577698B1 (ko) * 2014-04-07 2023-09-12 메조블라스트 인터내셔널 에스에이알엘 개선된 줄기 세포 조성물

Also Published As

Publication number Publication date
AU2022200640A1 (en) 2022-02-24
US20250136944A1 (en) 2025-05-01
JP7571109B2 (ja) 2024-10-22
US20190345452A1 (en) 2019-11-14
KR20160145066A (ko) 2016-12-19
AU2018200619B9 (en) 2020-05-07
JP2024177516A (ja) 2024-12-19
JP7196216B2 (ja) 2022-12-26
AU2018200619B2 (en) 2020-01-02
US20230030428A1 (en) 2023-02-02
CN106459913B (zh) 2021-05-18
KR20220080023A (ko) 2022-06-14
KR102405663B1 (ko) 2022-06-07
US10400218B2 (en) 2019-09-03
KR102577698B1 (ko) 2023-09-12
WO2015155187A1 (en) 2015-10-15
AU2024203197A1 (en) 2024-05-30
EP3129468A1 (en) 2017-02-15
CA2944262A1 (en) 2015-10-15
US20170107495A1 (en) 2017-04-20
AU2022200640B2 (en) 2024-02-15
CN106459913A (zh) 2017-02-22
AU2015243575B2 (en) 2017-11-02
SG10202000644TA (en) 2020-03-30
EP3129468B1 (en) 2022-09-21
SG11201607925SA (en) 2016-10-28
EP4137560A1 (en) 2023-02-22
JP2017512842A (ja) 2017-05-25
CA2944262C (en) 2023-08-01
AU2020202214B2 (en) 2021-11-18
AU2018200619A1 (en) 2018-02-15
AU2020202214A1 (en) 2020-04-16
US11312941B2 (en) 2022-04-26
JP2021080272A (ja) 2021-05-27
AU2015243575A1 (en) 2016-10-13
CN113337462A (zh) 2021-09-03
JP2023021279A (ja) 2023-02-10

Similar Documents

Publication Publication Date Title
JP7571109B2 (ja) 改善された幹細胞組成物
JP7009594B2 (ja) 免疫疾患の治療
CN107567494A (zh) 间充质干细胞的细胞培养方法
HK40088316A (en) Improved stem cell composition
US9359593B2 (en) Xeno-free generation of tissue-specific progenitor cells
HK1227933A1 (en) Improved stem cell composition
HK1227933B (en) Improved stem cell composition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180409

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210218

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210218

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210301

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210308

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210506

R150 Certificate of patent or registration of utility model

Ref document number: 6882161

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250